Tuesday, January 26, 2021
News

IIT Guwahati, Hester Biosciences collaborate to develop COVID-19 vaccine

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Guwahati | Wednesday, 2020 7:15:05 PM IST
Indian Institute of Technology Guwahati (IIT-G) on Wednesday announced a collaboration with pharmaceutical company Hester Biosciences Limited to develop a vaccine against coronavirus (COVID-19).

The vaccine is expected to be ready by the end of this year for animal studies. The work is currently in its early stage of development, IITG said in a statement.

The vaccine will be based on a recombinant avian paramyxovirus based vector platform. The recombinant avian paramyxovirus-1 will be used to express the immunogenic protein of SARS-CoV-2 virus.

The recombinant avian paramyxovirus-1 expressing the SARS-CoV-2 protein could be used as a vaccine candidate for further study, the Institute said.

"It is too early to comment on the efficacy and immunogenicity of the vaccine, however, we will be able to reveal more details about this vaccine after the results of animal studies are obtained," said researcher Dr Sachin Kumar, Associate Professor, Department of Biosciences and Bioengineering, IIT Guwahati.

According to the Institute, the avian paramyxovirus-1 has been explored as a vaccine vector for various animals and human pathogens.

The avian paramyxovirus-1 has been used to express the immunogenic protein of human pathogens such as HIV, avian influenza virus, human parainfluenza virus, SARS-CoV.

Similarly, it has also been explored as a vaccine vector for animal pathogens such as infectious bursal disease virus, infectious laryngotracheitis virus, bovine herpes virus, Nipah virus etc.

The research team has generated the recombinant avian paramyxovirus-1 based vaccine flatform for classical swine fever and Japanese encephalitis. The role of the Institute is to produce the recombinant vaccine candidate.

"IITG and Hester have collaborated to develop and manufacture a recombinant vaccine against COVID-19 disease as a preventive measure. Hester's involvement would be from master seed development up to release of the commercial vaccine," said Rajiv Gandhi, CEO and MD, Hester Biosciences Limited.

--IANS bu/na

( 312 Words)

2020-04-29-13:09:31 (IANS)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
WHO official warns of continued Covid tr...
Male breast cancer patients at increased...
Childhood cancer survivors not more like...
32 devotees in Magh Mela test positive f...
Nearly 20L beneficiaries vaccinated, hig...
AP seeks Centre's guidance for achieving...
More...
 
INDIA WORLD ASIA
India reports 9,102 new COVID-19 cases, ...
Several additional metro stations closed...
UP: Man dies after consuming poison duri...
5 killed as ambulance rams into truck in...
Police personnel sit on road in Nangloi ...
Airports Authority of India celebrates 7...
More...    
 
 Top Stories
Elizabeth Hurley goes topless in th... 
Israel halts all flights... 
'Harry Potter' series in works? Str... 
TDP leader diverts rejected Ramatee... 
Tibetan administration greets India... 
Islamabad perceives Biden as pro-Pa... 
Lalu's condition is stable, recover... 
Ex-WH Press Secretary to run for Ar...